Suppr超能文献

哮喘中远端气道炎症的治疗意义

Therapeutic significance of distal airway inflammation in asthma.

作者信息

Martin Richard J

机构信息

Department of Medicine, Pulmonary Division, National Jewish Medical and Research Center, Denver, CO 80206, USA.

出版信息

J Allergy Clin Immunol. 2002 Feb;109(2 Suppl):S447-60. doi: 10.1067/mai.2002.121409.

Abstract

Inflammation in asthma is not merely confined to the large central airways but also extends to the small peripheral airways. Distal lung inflammation can be observed even in patients with asthma with mild disease and normal spirometric readings. Subjects with asymptomatic asthma can exhibit significant increases in peripheral airway resistance, likely the result of distal lung inflammation. As determined from measurements of eosinophilic and other cellular infiltrates, the inflammatory response in the distal lung can exceed that in the large airways. Nocturnal asthma, a natural model of cyclic asthma worsening, is associated with an increase in nighttime distal lung inflammation, as evidenced by the accumulation of alveolar tissue eosinophils. Distal lung disease appears to increase the risk of recurrent asthma exacerbation, whereas disease-related anatomic changes in the small airways of the distal lung are prominent in fatal asthma. The clinical significance of distal lung disease makes this region an important therapeutic target. Chlorofluorocarbon (CFC)-based preparations of inhaled corticosteroids used to treat airway inflammation produce aerosols of relatively large particle size (approximately 4 microm); such aerosols have poor access to the distal lung. New formulations of inhaled corticosteroids that use hydrofluoroalkane (HFA) propellants can have smaller particle sizes (approximately 1 microm). Extrafine HFA aerosols have better access to the distal lung, with less oropharyngeal deposition. Imaging studies suggest that anti-inflammatory medication delivered as an extrafine aerosol produces beneficial changes in distal lung function. In one study, an HFA formulation of an inhaled corticosteroid reduced air trapping to a greater degree than a CFC formulation of the same corticosteroid. By extending the delivery of anti-inflammatory medication to the distal lung, the new HFA-based corticosteroids have the potential to treat asthma more effectively and at reduced steroid doses.

摘要

哮喘中的炎症不仅局限于大的中央气道,还会延伸至小的外周气道。即使是患有轻度疾病且肺功能测定读数正常的哮喘患者,也可观察到远端肺部炎症。无症状哮喘患者的外周气道阻力可能会显著增加,这可能是远端肺部炎症的结果。根据嗜酸性粒细胞和其他细胞浸润的测量结果,远端肺部的炎症反应可能超过大气道中的炎症反应。夜间哮喘是哮喘周期性恶化的自然模型,与夜间远端肺部炎症增加有关,肺泡组织嗜酸性粒细胞的积聚证明了这一点。远端肺部疾病似乎会增加哮喘复发加重的风险,而在致命性哮喘中,远端肺部小气道的疾病相关解剖学变化较为突出。远端肺部疾病的临床意义使其成为一个重要的治疗靶点。用于治疗气道炎症的基于氯氟烃(CFC)的吸入性糖皮质激素制剂会产生粒径相对较大(约4微米)的气雾剂;此类气雾剂难以到达远端肺部。使用氢氟烷烃(HFA)推进剂的新型吸入性糖皮质激素制剂的粒径可能更小(约1微米)。超细微HFA气雾剂更容易到达远端肺部,口咽部沉积较少。影像学研究表明,以超细微气雾剂形式递送的抗炎药物会使远端肺功能产生有益变化。在一项研究中,一种吸入性糖皮质激素的HFA制剂比相同糖皮质激素的CFC制剂能更大程度地减少气体潴留。通过将抗炎药物递送至远端肺部,新型基于HFA的糖皮质激素有潜力更有效地治疗哮喘,并降低类固醇剂量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验